Clovis Oncology (CLVS) Tops Q2 EPS by 3c

August 8, 2016 4:25 PM EDT
Get Alerts CLVS Hot Sheet
Trade CLVS Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Clovis Oncology (NASDAQ: CLVS) reported Q2 EPS of ($2.07), $0.03 better than the analyst estimate of ($2.10).

Clovis had $378.5 million in cash, cash equivalents and available-for-sale securities as of June 30, 2016. Cash used in operating activities was $68.0 million for the second quarter of 2016 and $151.7 million for the first half of 2016, compared with $57.2 million and $105.6 million for the comparable periods of 2015. Cash used in operating activities in the second quarter of 2016 was down $15.7 million, or 18.8 percent compared to the first quarter of 2016. Clovis had approximately 38.5 million outstanding shares of common stock as of June 30, 2016.

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment